DOCSLIB.ORG

Physician Prescribing of Opioids to Patients at Increased Risk of Overdose from Benzodiazepine Use in the United States

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Physician Prescribing of Opioids to Patients at Increased Risk of Overdose from Benzodiazepine Use in the United States Supplementary Online Content Ladapo JA, Larochelle MR, Chen A, et al. Physician prescribing of opioids to patients at increased risk of overdose from benzodiazepine use in the United States. JAMA Psychiatry. Published online April 12, 2018. doi:10.1001/jamapsychiatry.2018.0544 eTable 1. Multum Lexicon Generic Drug Codes and NCHS Generic Codes (5-Digit Code Assigned to Each Official Generic Name Assigned to Every Drug Entity by the United States Pharmacopeia) eTable 2. Rate of New Opioid Prescriptions in US Population, 2005-2015 (Sensitivity Analysis in Which up to 30 Medications Were Assessed) eTable 3. Pain-Related Reasons for Visit and Diagnoses eTable 4. Rate of New Opioid Prescriptions in US Population, 2005-2015 (Sensitivity Analysis Limiting Data to NAMCS Only, Without NHAMCS/Community Health Center Data) This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 eTable 1. Multum Lexicon Generic Drug Codes and NCHS Generic Codes (5-Digit Code Assigned to Each Official Generic Name Assigned to Every Drug Entity by the United States Pharmacopeia) Opioids and Naloxone List Drug Drug Notes Drug Drug Notes Code Code Acetaminophen, a11047 Brompheniramine w/ 04855 Caffeine, Codeine, Codeine DC Salicylamide Expectoran Acetaminophen, 00280 Acetaminophen Brompheniramine, a11065 Codeine with Codeine Codeine, Guaifenesin, Phenylephrine, Phenylpropanolamine Acetaminophen, 32915 Tylenol no. 2 with Buprenorphine 10386 Butrans Codeine Codeine Acetaminophen, 32920 Tylenol no. 3 with Buprenorphine HCL 60265 Buprenex Codeine Codeine Acetaminophen, 32925 Tylenol no. 4 with Buprenorphine HCL 95036 Buprenorphine Codeine Codeine Acetaminophen, 32930 Tylenol with Buprenorphine HCL 50711 Buprenorphine Codeine Codeine Acetaminophen, 32935 Tylenol with Buprenorphine, 10166 Codeine Codeine Elixir Naloxone Acetaminophen, 23680 Phenaphen with Buprenorphine, 03276 Suboxone Codeine Codeine Naloxone Acetaminophen, d03423 Acetaminophen Buprenorphine, 13141 Zubsolv Codeine with Codeine Naloxone Acetaminophen, 00283 Buprenorphine, d04819 Oxycodone Naloxone Acetaminophen, 12046 Percocet Buprenorphine- 10166 Oxycodone Naloxone Acetaminophen, 23385 Percocet-5 Butalbital, 95178 Fioricet with Oxycodone Acetaminophen, Codeine Caffeine, and Codeine Phosphate Acetaminophen, 07252 Percocet 7.5 Butalbital, d03425 Fioricet with Oxycodone Acetaminophen, Codeine Caffeine, and Codeine Phosphate Acetaminophen, 07251 Percocet 10 Butalbital, n08029 Oxycodone Acetaminophen, Caffeine, Codeine Acetaminophen, 99114 Endocet Butalbital, ASA, 10238 Oxycodone Caffeine, Codeine Butalbital, d03425 Fioricet with Butalbital, ASA, 12570 Trade name © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 Acetaminophen, Codeine Caffeine, Codeine Fiorinal With Caffeine, and Codeine Codeine #3 Phosphate Butalbital, n08029 Butalbital, ASA, d03426 Acetaminophen, Caffeine, Codeine Caffeine, Codeine Butalbital, ASA, 10238 Butorphanol 01021 Butorphanol Caffeine, Codeine Tartrate Butalbital, ASA, 12570 Trade name Butorphanol 29285 Stadol Caffeine, Codeine Fiorinal With Codeine #3 Butalbital, ASA, d03426 Butorphanol 50740 Butorphanol Caffeine, Codeine Tartrate Butorphanol 01021 Butorphanol Chlorpheniramine, d03416 Zutripro Tartrate Hydrocodone, Pseudoephedrine Butorphanol 29285 Stadol Codeine 07180 Butorphanol 50740 Butorphanol Codeine 51340 Tartrate Butorphanol d00838 Butorphanol Codeine d00012 Tartrate Chlorpheniramine, 06244 ZTuss Expectorant Codeine Phosphate 07185 Guaifenesin, Hydrocodone, Phenylalanine, Pseudoephedrine Chlorpheniramine, a11760 ZTuss Expectorant Codeine, Guaifenesin 13838 Guaifenesin, Hydrocodone, Phenylalanine, Pseudoephedrine Chlorpheniramine, 08228 Chlorpheniramine Codeine, Guaifenesin 95044 Robitussin w/ Hydrocodone Hydrocodone Codeine Chlorpheniramine, 04256 Hydrocodone GF Codeine, Guaifenesin d03393 Hydrocodone Chlorpheniramine, d03356 Chlorpheniramine Codeine, 25430 Promethazine Hydrocodone Hydrocodone Phenylephrine, VC with Promethazine Codeine Chlorpheniramine, 08452 Tussionex Codeine, d03364 Promethazine Hydrocodone, Polistirex Pennkinetic Phenylephrine, VC with Promethazine Codeine Chlorpheniramine, 09147 Tussicaps Codeine, Promethazine 25432 Promethazine Hydrocodone, Polistirex with Codeine Chlorpheniramine, 11402 Zutripro Codeine, Promethazine 23798 Phenergan with Hydrocodone, Codeine is trade Pseudoephedrine name © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 Codeine, Promethazine d03357 Promethazine with Codeine, Promethazine 25390 Promethazine Codeine Expectorant with Codeine Codeine, 32558 Triprolidine Codeine, Promethazine 25415 Promethazine Pseudoephedrine, Pseudophed with HCl with Triprolidine Codeine Codeine Expectorant Codeine, d03363 Triprolidine Hydrocodone Bitartrate 89038 Hydrocodone Pseudoephedrine, Pseudophed with Bitartrate with Triprolidine Codeine APAP Codeine-Sulfate 07190 Hydrocodone Bitartrate 98036 Norco Codeine-Sulfate 70360 Hydrocodone Bitartrate 70217 Hydrocodone Bitartrate with APAP Dezocine 57046 Dalgan Hydrocodone Bitartrate 14770 Hycodan and Homatropine Methylbromide Dihydrocodeine 09574 Hydrocodone 32855 Tussionex Polistirex, Chlorpheniramine Dihydrocodeine 52647 Hydrocodone 70599 Tussionex Polistirex, Chlorpheniramine Dihydrocodeine d03168 Hydrocodone a10956 Tussionex Polistirex, Chlorpheniramine Dihydrocodeine, 70405 Trezix Hydrocodone, 89039 Bitartrate / Acetaminophen Acetaminophen, Caffeine, Dihydrocodeine Dihydrocodeine, d04269 Trezix Hydrocodone, 92041 Hydrocodone Bitartrate / Acetaminophen compound Acetaminophen, Caffeine, Dihydrocodeine Ethylmorphine 52165 Hydrocodone, 34110 Vicodin Acetaminophen Fentanyl 94188 Fentanyl Hydrocodone, 00251 Vicodin ES Acetaminophen Fentanyl 52225 Fentanyl Hydrocodone, 08354 Vicodin HP Acetaminophen Fentanyl d00233 Fentanyl Hydrocodone, 98104 Vicodin Tuss Acetaminophen Fentanyl Citrate 60565 Fentanyl Citrate Hydrocodone, 01268 Lorcet Plus Acetaminophen © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 Fentanyl Citrate 70452 Fentanyl Citrate Hydrocodone, 93089 Lorcet Acetaminophen Fentanyl transdermal 92024 Duragesic Hydrocodone, 02132 Lorcet HD system (Fentanyl Acetaminophen Transdermal) Fentanyl Transmucosal 02067 Actiq Hydrocodone, 92180 Lortab Lozenge Acetaminophen Fentanyl Transmucosal 70731 Actiq Hydrocodone, 02314 Lortab elixir Lozenge Acetaminophen Guaifenesin, d03396 Hydrocodone, 02082 Maxidone Hydrocodone Acetaminophen Homatropine, 05223 Homatropine- Hydrocodone, 96028 Acetaminophen- Hydrocodone Hydrocodone Acetaminophen Hydrocodone Homatropine, d03340 Homatropine- Hydrocodone, d03428 Hydrocodone Hydrocodone Acetaminophen Homatropine, Methyl a10897 Hydrocodone, 09751 Bromide, Hydrocodone Ibuprofen Hydrocodone 14955 Hydrocodone Hydrocodone, 98043 Vicoprofen Ibuprofen Hydrocodone 52650 Hydrocodone Hydrocodone, d04225 Ibuprofen Hydrocodone d03075 Hydrocodone Hydromorphone 15005 Hydromorphone Methadone 53475 Methadone Hydromorphone 11229 Exalgo Methadone d00050 Methadone Hydromorphone 52670 Hydromorphone Morphine 19650 Morphine Hydromorphone d00255 Hydromorphone Morphine 19655 Morphine & Hydromorphone HCL 09600 Dilaudid Atropine Morphine 53760 Morphine Hydromorphone HCL 09595 Dilaudid Cough Syrup Morphine d00308 Morphine Hydromorphone HCL 70623 Dilaudid Morphine Sulfate 99123 Levorphanol 17362 Levorphanol Tartrate (Levo- Dromoran) Morphine Sulfate 12008 Morphine ER Levorphanol 53055 Levorphanol Tartrate (Levo- Dromoran) Morphine Sulfate 41420 Roxanol Levorphanol d00825 Levorphanol Tartrate (Levo- Dromoran) Morphine Sulfate 19699 MS-Contin Meperidine 18760 Meperidine Morphine Sulfate 03228 Avinza Meperidine 96405 Demerol Morphine Sulfate 98144 Kadian Meperidine 53335 Meperidine Morphine Sulfate 70044 Meperidine d00017 Meperidine Nalbuphine 60990 Nalbuphine HCL Meperidine HCL 00200 Meperidine HCL Nalbuphine 21550 Nubain Meperidine HCL 70267 Meperidine HCL © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 Nalbuphine 53855 Nalbuphine HCL Methadone 18985 Methadone Nalbuphine d00839 Nalbuphine HCL Methadone 10130 Dolophine Naloxone d00311 Naloxone 53865 Narcan 20310 Naloxone HCl 60995 Oxycodone 12028 Oxymorphone 11270 Oxycodone 96109 Oxycontin Oxymorphone HCl 07117 Opana Oxycodone 09582 Oxycodone CR Oxymorphone HCl 07223 Opana ER Oxycodone 05081 OxyIR Pentazocine 23285 Oxycodone 54094 Pentazocine 70591 Pentazocine HCl Oxycodone d00329 Pentazocine 54290 Oxycodone HCL 22303 Pentazocine d00334 Oxycodone HCL 08246 Oxycodone ER Pentazocine, 07701 Acetaminophen Oxycodone HCL 02333 Roxicodone Pentazocine, 30513 Talacen Acetaminophen Oxycodone HCL 70269 Pentazocine, 70951 Acetaminophen Oxycodone HCL, 22305 Oxycodone HCL Pentazocine, d03682 Acetaminophen & Acetaminophen Acetaminophen Oxycodone 70582 Pentazocine, Naloxone 13117 Terephthalate Oxymorphone 54135 Pentazocine, Naloxone 04538 Talwin Nx Oxymorphone d00833 Pentazocine, Naloxone 30535 Talwin Pentazocine, Naloxone d03676 Tapentadol d07453 Phenylpropanolamin, 14960 Hydrocodone PA Tramadol 96041 Tramadol Hydrocodone Syrup Sufentanil Citrate 50040 Sufenta Tramadol 95050 Ultram Sufentanil Citrate 55583 Sufenta Tramadol 08329 Ultram ER Tapentadol 09286 Tramadol 57160 Tramadol Tapentadol 11121 Nucynta Tramadol d03826 Tramadol Tramadol
Load more

Recommended publications
  • Chronic Use of Opioid Medications Before and After Bariatric Surgery
    Supplementary Online Content Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. doi:10.1001/jama.2013.278344 eFigure. Opioid Dispensings in 60 Days Before and 60 Days After Bariatric Surgery eTable 1. Opioid Classification and Morphine Equivalents Conversion Factors for Opioids Administered by Tablet, Capsule, Liquid, Transdermal Patch, and Transmucosal Formulations eTable 2. ICD-9 Codes for Comorbid Diagnosis of Substance Abuse, Anxiety, Posttraumatic Stress Disorder, and/or Depression eTable 3. ICD-9 Codes for Inclusion and Exclusion of Chronic Pain Diagnoses eTable 4. Therapeutic Classes, Generic Names, and Selected Brand Names of Covariate Medications eTable 5. Types of Opioids Dispensed During the Year Before and the Year After Bariatric Surgery Among Presurgery Chronic Opioid Users eTable 6. Types of Opioids Used Before and After Bariatric Surgery Among 933 Individuals With Chronic Opioid Use Before Bariatric Surgery eTable 7. Unadjusted Characteristics of Chronic Opioid Users According to Whether or Not Both Presurgery and Postsurgery Body Mass Indexes (BMIs) Data Were Available eTable 8. Presurgery and Postsurgery Use of Opioids and Selected Other Analgesic and Adjunctive Pain Medication Classes Among Presurgery Chronic Opioid Users With Presurgery Chronic Pain Diagnoses This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From:
    [Show full text]
  • 2.0 Synopsis
    Hydrocodone/Acetaminophen Extended Release Tablets M12-807 Abbreviated Clinical Study Report R&D/11/661 2.0 Synopsis Abbott Laboratories Individual Study Table Referring (For National Authority to Part of Dossier: Use Only) Name of Study Drug: Volume: Hydrocodone/Acetaminophen Extended Release Page: Name of Active Ingredient: Hydrocodone 10 mg/ Acetaminophen 650 mg Extended Release Title of Study: A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects with Chronic Low Back Pain Coordinating Investigator: Study Sites: Seventeen investigative sites in the United States Publications: None Studied Period (Years): Phase of Development: 2 First Subject First Visit: 22 June 2011 Last Subject Last Visit: 28 October 2011 Objectives: The primary objective of this study was to compare the analgesic efficacy and safety of 1 tablet of hydrocodone/acetaminophen extended release 10 mg/650 mg administered twice daily over 2 weeks to placebo in subjects with moderate to moderately severe chronic low back pain (CLBP). A secondary objective of this study was to explore the population pharmacokinetics of hydrocodone and acetaminophen resulting from administration of hydrocodone/acetaminophen extended release 10 mg/650 mg tablets. Methodology: This Phase 2, multicenter, double-blind (DB), placebo-controlled, randomized withdrawal study compared the analgesic efficacy and safety of 1 tablet hydrocodone/acetaminophen extended release 10 mg/650 mg to placebo in subjects with moderate to moderately severe CLBP. Subjects met pre-defined criteria at the conclusion of the Open-Label (OL) Titration Period to proceed to randomization into the DB Maintenance Period of the study.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Opioid Powders Page: 1 of 9
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
    [Show full text]
  • BUTALBITAL ANALGESICS Allzital (Butalbital-Acetaminophen
    BUTALBITAL ANALGESICS Allzital (butalbital-acetaminophen), butalbital-aspirin-caffeine, butalbital-aspirin-caffeine- codeine, butalbital-acetaminophen, butalbital-acetaminophen-caffeine, butalbital- acetaminophen-caffeine-codeine, Vanatol LQ (butalbital-acetaminophen-caffeine liquid oral solution) RATIONALE FOR INCLUSION IN PA PROGRAM Background Butalbital containing products are non-opioid analgesics that contain a combination of different drug products indicated for the relief of the symptom complex of tension (or muscle contraction) headache pain. Butalbital is a short to intermediate-acting barbiturate that works in concert with acetaminophen, an antipyretic non-salicylate agent, aspirin, a pain-relieving NSAID, and caffeine, a stimulant that works in the CNS, to decrease pain via a mechanism that isn’t well understood. Butalbital is a habit-forming drug that potentiates the effects of other commonly abuse drugs or substances like alcohol. Caffeine might help increase vasodilation and smooth muscle relaxation, while butalbital is thought to help balance the CNS stimulation caused by caffeine and produces depressant effects (1). Regulatory Status FDA approved indication: Butalbital containing products are used in the relief of the symptom complex of tension or muscle contraction headaches (2-8). Frequent use of acute medications is generally thought to cause medication-overuse headache. To decrease the risk of medication-overuse headache (“rebound headache” or “drug-induced headache”) many experts limit acute therapy to two headache days per week on a regular basis. Based on concerns of overuse, medication-overuse headache, and withdrawal, the use of butalbital-containing analgesics should be limited and carefully monitored. The Allzital limit is set to the maximum of 12 doses per day for acute treatment of 8 headaches per month as this product contains less butalbital than other products.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products
    OPIOID IR COMBO DRUGS Apadaz* (benzhydrocodone-acetaminophen), Codeine-acetaminophen, Dvorah* (dihydrocodeine-caffeine-acetaminophen*), Hydrocodone-acetaminophen, Hydrocodone- acetaminophen solution 10-325mg*, Hydrocodone-ibuprofen, Nalocet* (oxycodone- acetaminophen*), Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Primlev*/Prolate* (oxycodone-acetaminophen*), Tramadol-acetaminophen, Trezix (dihydrocodeine-caffeine-acetaminophen) *Prior authorization for certain non-covered formulations applies only to formulary exceptions Pre - PA Allowance Age 12 years of age or older – Ultracet (tramadol and acetaminophen) and Codeine/APAP products Quantity Patients 18 years or older will be able to fill the Pre-PA Allowance after they have filled an initial 7 day supply of IR opioid therapy or if they have been on IR or ER opioid therapy in the last 180 days Patients age 17 and under will require a PA after they have filled a 3 day supply of the Pre- PA Allowance Patients with opioid addiction treatment or methadone in the last 30 days will not be eligible for Pre-PA Allowance Immediate Release Tablets or Capsules ≤ 50 MME/day Medication Strength Quantity Limit Codeine/APAP soln 120-12 mg/5 mL Hydrocodone/APAP soln 7.5/325 mg/15 mL 5400 mL per 90 days Hydrocodone/APAP elixir 10/300 mg/15 mL Oxycodone/APAP soln 5-325 mg/5 mL 3000 mL per 90 days Hydrocodone/ibuprofen 5/200 mg, 7.5/200 mg, 10/200 mg 270 units per 90 days Oxycodone/ibuprofen 5/400 mg Oxycodone/APAP 10/325 mg Codeine/APAP 60/300 mg Hydrocodone/APAP 7.5/300 mg, 7.5/325
    [Show full text]
  • Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules
    Medication Guide Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, C III Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are: • A strong prescription pain medicine that contains an opioid (narcotic) that is indicated for the relief of the symptom complex of tension (or muscle contraction) headache, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them. • An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death. Important information about Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules: • Get emergency help right away if you take too much Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules (overdose). When you first start taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. • Taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death. • Never give anyone else your Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules. They could die from taking it. Store Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules away from children and in a safe place to prevent stealing or abuse. Selling or giving away Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is against the law. • Get emergency help right away if you take more than 4,000 mg of acetaminophen in 1 day.
    [Show full text]
  • Picquestion of the Week:1/09/12
    Grand Teton, Wyoming USA PIC QUESTION OF THE WEEK: 1/09/12 Q: Can fentanyl be prescribed for a patient allergic to codeine? A: Opioid analgesics are among the most commonly prescribed drugs in the United States. True allergic reactions to opioid analgesics are extremely rare, dependent upon antibody (usually IgE/IgG), and triggered by histamine and other mediators. Immediate reactions (e.g. anaphylaxis) are associated with contraction of smooth muscle, vasodilation, increased mucous secretion, and enhanced vasopermeability. More frequently, opioids such as morphine and codeine cause direct release of histamine from mast cells. These reactions are considered idiosyncratic, independent of antibody, and based on individual patient susceptibility. Direct release of histamine is the most common mechanism for the development of urticaria, pruritus, etc. in patients receiving natural opioids such as morphine and codeine. Opioid analgesics are typically classified according to the source of the chemical or the presence of structurally related groups (see table). In general, the risk of cross-reactivity is thought to be less likely among agents from a different source or structural class. If a reaction to morphine or codeine is severe in nature, substituting a synthetic or semi-synthetic agent or a structurally dissimilar compound appears to reduce the risk of cross-reactivity. It should be noted that although tramadol is classified as a synthetic opioid derivative, there have been cases of severe hypersensitivity reactions associated with its use. These cases have occurred in patients with and without a history of allergic reactions to opiates. Thus tramadol would probably not a good first alternative in a patient with a history of a severe reaction to this group of drugs.
    [Show full text]
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology
    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
    [Show full text]